CellCentric is a clinical-stage biotechnology company focused on developing innovative cancer treatments, particularly through its lead drug candidate, inobrodib. This first-in-class oral small molecule inhibitor specifically targets the p300 and CBP proteins, which are critical in the regulation of gene expression related to tumor progression. By binding to the bromodomain of these proteins, inobrodib disrupts their co-activation of genes such as IRF4 and MYC, which are implicated in various cancers, including multiple myeloma. The drug's selective mechanism of action allows it to inhibit cancer cell growth while minimizing effects on other proteins, making it a promising candidate for targeted cancer therapy.

Inobrodib is currently undergoing extensive clinical trials, having transitioned from initial safety evaluations to more advanced studies that explore its efficacy as both a monotherapy and in combination with existing treatments. The oral administration of inobrodib is a significant advantage, as it allows patients to take the medication at home, reducing the need for hospital visits and enhancing patient comfort and compliance. CellCentric's commitment to patient-focused drug development aims to transform cancer treatment outcomes, with ongoing research into various hematological malignancies and solid tumors.

United Kingdom

Inobrodib is the first small molecule drug in the clinic targeting twin proteins p300 and CBP. It is formulated as a capsule taken orally.

p300/CBP are twin (paralogue) acetyl transferases, and importantly, gene activating proteins that are known to play an important role in the progression of certain cancers.

CellCentric’s pioneering drug is in Phase I/II clinical trials to evaluate its effectiveness to treat specific solid tumours, as well as haematological malignancies (blood cancers).  These represent major clinical unmet needs, delivering a new therapy for people with cancer, who otherwise have few alternatives.

CellCentric

Company Details